欢迎访问《现代生物医学进展》编辑部！

摘要目的：观察不同剂量氟伐他汀对冠心病伴血脂增高患者的临床效果及安全性，为临床治疗提供依据。方法：选择我院2010 年5 月～2013年2 月收治的96例冠心病伴高脂血症患者并将其进行随机分组，即20 mg 及40 mg 氟伐他汀治疗组各48 例，观察和比较两组的临床疗效及不良反应的发生情况。结果：经4 周、8 周治疗后，两组患者的总胆固醇(TC)、低密度脂蛋白胆固醇 (LDL-C)、甘油三酯(TG)的水平均较同组治疗前显著降低，差异均具有统计学意义(P<0.05)；高密度脂蛋白胆固醇(HDL-C)均较同组治疗前明显升高，差异有统计学意义(P<0.05)；40 mg 组hs-CRP含量下降，较20mg 组显著，差异明显具有统计学意义(P<0.05)。结论：对于冠心病伴血脂增高患者，采用高剂量氟伐他汀进行降脂治疗临床疗效较好，且安全性高，建议推广应用。

英文摘要:

ABSTRACT Objective:To observe the different doses of fluvastatin on coronary heart disease in patients with elevated blood lipids, clinical efficacy and safety,provide the basis for clinical treatment. Methods:The hospital in May 2010-February 2013 period were treated 96 cases of patients with coronary artery disease and hyperlipidemia were randomized, of which 40mg 20 mg group and 48 cases in each group. Respectively, according to each group to give the corresponding lipid-lowering therapy with fluvastatin, compared the clinical efficacy and adverse reactions. Results:The two groups of patients after four weeks, eight weeks after treatment, TC, LDL-C, TG levels compared with before treatment significantly reduced, significant differences were statistically significant (P <0.05). The two groups of patients taking fluvastatin treatment for 4 weeks, 8 weeks after HDL-C was significantly higher than that before treatment, the difference was statistically significant (P <0.05). Two groups, 40mg group hs-CRP levels were significantly decreased compared to 20mg, significant differences were statistically significant (P <0.05). Conclusion:For patients with coronary artery disease and elevated blood lipids, high doses of fluvastatin for lipid-lowering therapy better clinical efficacy and safety, the proposed application.

View Full Text View/Add Comment Download reader